Celldex Therapeutics, Inc. (NASDAQ:CLDX)‘s stock
Post# of 22755
Posted On: 04/21/2016 7:28:52 PM
Celldex Therapeutics, Inc. (NASDAQ:CLDX)‘s stock had its “buy” rating restated by equities researchers at Roth Capital in a research report issued to clients and investors on Tuesday, Market Beat reports. They presently have a $7.00 price target on the biopharmaceutical company’s stock. Roth Capital’s price target suggests a potential upside of 75.00% from the stock’s current price.
Several other equities research analysts have also commented on CLDX. Brean Capital reaffirmed a “buy” rating and set a $24.00 price target on shares of Celldex Therapeutics in a research report on Tuesday, March 8th. Leerink Partner lowered shares of Celldex Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Monday, March 7th. Leerink Swann lowered shares of Celldex Therapeutics from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $30.00 to $4.00 in a research report on Monday, March 7th. Wedbush reaffirmed an “outperform” rating and set a $24.00 price target on shares of Celldex Therapeutics in a research report on Thursday, February 25th. Finally, Cowen and Company reaffirmed an “outperform” rating and set a $12.00 price target (down previously from $28.00) on shares of Celldex Therapeutics in a research report on Tuesday, March 8th. Seven equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Celldex Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $16.80.
A number of large investors recently made changes to their positions in the stock. Numeric Investors LLC bought a new stake in shares of Celldex Therapeutics during the fourth quarter worth about $1,778,000. Columbia Wanger Asset Management LLC raised its stake in shares of Celldex Therapeutics by 16.1% in the fourth quarter. Columbia Wanger Asset Management LLC now owns 3,610,008 shares of the biopharmaceutical company’s stock worth $56,605,000 after buying an additional 500,393 shares during the period. Columbus Circle Investors raised its stake in shares of Celldex Therapeutics by 10.5% in the fourth quarter. Columbus Circle Investors now owns 655,739 shares of the biopharmaceutical company’s stock worth $10,282,000 after buying an additional 62,246 shares during the period. Bedell Frazier Investment Counseling LLC raised its stake in shares of Celldex Therapeutics by 9.0% in the fourth quarter. Bedell Frazier Investment Counseling LLC now owns 65,236 shares of the biopharmaceutical company’s stock worth $1,023,000 after buying an additional 5,411 shares during the period. Finally, Tocqueville Asset Management L.P. raised its stake in shares of Celldex Therapeutics by 54.9% in the fourth quarter. Tocqueville Asset Management L.P. now owns 73,400 shares of the biopharmaceutical company’s stock worth $1,151,000 after buying an additional 26,000 shares during the period.
Celldex Therapeutics (NASDAQ:CLDX) traded up 2.00% on Tuesday, hitting $4.08. 1,638,701 shares of the company’s stock were exchanged. Celldex Therapeutics has a 52-week low of $2.96 and a 52-week high of $30.28. The stock’s market cap is $402.71 million. The firm has a 50 day moving average price of $4.31 and a 200-day moving average price of $10.42.
Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings results on Thursday, February 25th. The biopharmaceutical company reported ($0.33) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.35) by $0.02. The business had revenue of $1.80 million for the quarter, compared to analysts’ expectations of $0.80 million. Celldex Therapeutics’s revenue for the quarter was up 21.1% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.36) EPS. Analysts predict that Celldex Therapeutics will post ($1.33) earnings per share for the current fiscal year.
Celldex Therapeutics, Inc is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company is engaged in the development of targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that treat cancers and other diseases.
Several other equities research analysts have also commented on CLDX. Brean Capital reaffirmed a “buy” rating and set a $24.00 price target on shares of Celldex Therapeutics in a research report on Tuesday, March 8th. Leerink Partner lowered shares of Celldex Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Monday, March 7th. Leerink Swann lowered shares of Celldex Therapeutics from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $30.00 to $4.00 in a research report on Monday, March 7th. Wedbush reaffirmed an “outperform” rating and set a $24.00 price target on shares of Celldex Therapeutics in a research report on Thursday, February 25th. Finally, Cowen and Company reaffirmed an “outperform” rating and set a $12.00 price target (down previously from $28.00) on shares of Celldex Therapeutics in a research report on Tuesday, March 8th. Seven equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Celldex Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $16.80.
A number of large investors recently made changes to their positions in the stock. Numeric Investors LLC bought a new stake in shares of Celldex Therapeutics during the fourth quarter worth about $1,778,000. Columbia Wanger Asset Management LLC raised its stake in shares of Celldex Therapeutics by 16.1% in the fourth quarter. Columbia Wanger Asset Management LLC now owns 3,610,008 shares of the biopharmaceutical company’s stock worth $56,605,000 after buying an additional 500,393 shares during the period. Columbus Circle Investors raised its stake in shares of Celldex Therapeutics by 10.5% in the fourth quarter. Columbus Circle Investors now owns 655,739 shares of the biopharmaceutical company’s stock worth $10,282,000 after buying an additional 62,246 shares during the period. Bedell Frazier Investment Counseling LLC raised its stake in shares of Celldex Therapeutics by 9.0% in the fourth quarter. Bedell Frazier Investment Counseling LLC now owns 65,236 shares of the biopharmaceutical company’s stock worth $1,023,000 after buying an additional 5,411 shares during the period. Finally, Tocqueville Asset Management L.P. raised its stake in shares of Celldex Therapeutics by 54.9% in the fourth quarter. Tocqueville Asset Management L.P. now owns 73,400 shares of the biopharmaceutical company’s stock worth $1,151,000 after buying an additional 26,000 shares during the period.
Celldex Therapeutics (NASDAQ:CLDX) traded up 2.00% on Tuesday, hitting $4.08. 1,638,701 shares of the company’s stock were exchanged. Celldex Therapeutics has a 52-week low of $2.96 and a 52-week high of $30.28. The stock’s market cap is $402.71 million. The firm has a 50 day moving average price of $4.31 and a 200-day moving average price of $10.42.
Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings results on Thursday, February 25th. The biopharmaceutical company reported ($0.33) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.35) by $0.02. The business had revenue of $1.80 million for the quarter, compared to analysts’ expectations of $0.80 million. Celldex Therapeutics’s revenue for the quarter was up 21.1% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.36) EPS. Analysts predict that Celldex Therapeutics will post ($1.33) earnings per share for the current fiscal year.
Celldex Therapeutics, Inc is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company is engaged in the development of targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that treat cancers and other diseases.
(0)
(0)
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
Scroll down for more posts ▼